US Nabs Last-Minute Waiver from EC to Export APIs to Europe

By Zachary Brennan contact

- Last updated on GMT

US Nabs Last-Minute Waiver from EC to Export APIs to Europe

Related tags: Falsified medicines directive, European union

In an effort to stave off expected drug shortages, the EC has approved a waiver that will allow US API manufacturers to export their products to Europe.

Beginning July 2, all APIs (active pharmaceutical ingredients) sent to the European Union will require written confirmation from local regulators that their manufacturing practices comply with European GMP (good manufacturing practices) due to the Falsified Medicines Directive enacted in 2011. 

The EC’s (European Commission) decision to grant the waiver may have saved the EU from drug shortages​ as many of the drugs produced in the region rely on US APIs. 

Working with the EC, the FDA has helped U.S. pharmaceutical companies avoid duplicative administrative efforts which impede trade and delay the manufacture of needed medicines​,” FDA Commissioner Margaret Hamburg said. “At the same time, the FDA applauds Europe for taking steps to protect its pharmaceutical supply chain and will continue to collaborate with its regulatory counterparts around the world to help keep our own supply chain safe​.” 

Other Countries​ 

As far as other countries are concerned, the results of expected compliance still vary. The EC previously granted waivers​ to Australia, Japan and Switzerland, though the vast majority of APIs are imported from China and India. 

A Beijing industry group announced earlier this month​ that some Chinese firms will not have the necessary written confirmations, while India’s CDSCO (Central Drugs Standards Control Organization) published a list of the companies that have obtained the confirmations, which the EC welcomed​. 

But there still seem to be some lingering concerns about shortages as the UK’s MHRA last week announced​ a contingency plan that would allow API imports without the written confirmation if there are drug supply concerns. The pharmaceutical industry is lobbying for other EU Member States to take similar action.

Related topics: Markets & Regulations, Ingredients

Related news

Show more